Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target Clostridioides difficile

The US Centers for Disease Control and Prevention (CDC) lists Clostridioides difficile as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of C. difficile infections as of this writing, while the global pipeline of new drugs is sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dahyun, Kim, Young-Rok, Hwang, Hee-Jong, Ciufolini, Marco A., Lee, Jusuk, Lee, Hakyeong, Clovis, Shyaka, Jung, Sungji, Oh, Sang-Hun, Son, Young-Jin, Kwak, Jin-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142968/
https://www.ncbi.nlm.nih.gov/pubmed/35631450
http://dx.doi.org/10.3390/ph15050623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142968/
https://www.ncbi.nlm.nih.gov/pubmed/35631450
http://dx.doi.org/10.3390/ph15050623

Ejemplares similares